Underrecognition and Undertreatment of Dementia in Italian Nursing Homes

Journal of the American Medical Directors Association

Volumn 13, Issue 8, 2012, Pages 759.e7-759.e13

  Cherubini, Antonio ^a,b   Ruggiero, Carmelinda ^b   Dell'Aquila, Giuseppina ^b   Eusebi, Paolo ^c   Gasperini, Beatrice ^b   Zengarini, Elisa ^b   Cerenzia, Annarita ^b   Zuliani, Giovanni ^d   Guaita, Antonio ^e   Lattanzio, Fabrizia ^a  

^a INRCA   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c Regional Health Authority of Umbria   (Italy)

^d UNIVERSITY OF FERRARA   (Italy)

^e Golgi Cenci Foundation   (Italy)

Author keywords

Cholinesterase inhibitor; Dementia; Memantine; Nursing homes; Underdiagnosis; Undertreatment

Indexed keywords

CHOLINESTERASE INHIBITOR; MEMANTINE;

AGED; ALZHEIMER DISEASE; ARTICLE; COGNITIVE DEFECT; COGNITIVE PERFORMANCE SCALE; COHORT ANALYSIS; DEMENTIA; DISEASE SEVERITY; FEMALE; GERIATRIC ASSESSMENT; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; NURSING HOME PATIENT; PREVALENCE; PSYCHOLOGICAL RATING SCALE; PUBLIC HEALTH SERVICE;

EID: 84866760795     PISSN: 15258610     EISSN: 15389375     Source Type: Journal    
DOI: 10.1016/j.jamda.2012.05.015     Document Type: Article

References (58)

1. Magaziner J., German P., Zimmerman S.I., et al. The prevalence of dementia in a statewide sample of new nursing home admissions aged 65 and older: Diagnosis by expert panel. Gerontologist 2000, 40:663-672.
2. Bernstein B., Remsburg R.E. Estimated prevalence of people with cognitive impairment: Results from nationally representative community and institutional surveys. Gerontologist 2007, 47:350-354.
3. Matthews F.E., Dening T. Prevalence of dementia in institutional care. Lancet 2002, 360:225-226.
4. Gaugler J.E., Duval S., Anderson K.A., et al. Predicting nursing home admission in the US: A meta-analysis. BMC Geriatr 2007, 7:13.
5. Dramé M., Lang P.O., Jolly D., et al. Nursing home admission in elderly subjects with dementia: Predictive factors and future challenges. J Am Med Dir Assoc 2012, 13:83.e17-83.e20.
6. Gaugler J.E., Krichbaum K., Wyman J.F. Predictors of nursing home admission for persons with dementia. Med Care 2009, 47:191-198.
7. Nygaard H.A., Ruths S. Missing the diagnosis: Senile dementia in patients admitted to nursing homes. Scand J Prim Health Care 2003, 21:148-152.
8. Cahill S., Diaz-Ponce A.M., Coen R.F., Walsh C. The underdetection of cognitive impairment in nursing homes in the Dublin area. The need for on-going cognitive assessment. Age Ageing 2010, 39:128-131.
9. NICE (National Institute for Health and Clinical Excellence) technology appraisal guidance 111. Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease (amended). August 2009. Available at: Accessed February 15, 2012. http://www.nice.org.uk.
10. Emre M., Aarsland D., Albanese A., et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004, 351:2509-2518.
11. Touchon J., Bergman H., Bullock R., et al. Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology. Curr Med Res Opin 2006, 22:49-59.
12. Rodda J., Carter J. Cholinesterase inhibitors and memantine for symptomatic treatment of dementia. BMJ 2012, 344:e2986.
13. Tariot P.N., Cummings J.L., Katz I.R., et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc 2001, 49:1590-1599.
14. Pedone C., Lapane K.L., Mor V., et al. Donepezil use in US nursing homes. Aging Clin Exp Res 2004, 16:60-67.
15. Bright-Long L. Alzheimer's treatment in nursing homes: Room for improvement. J Am Med Dir Assoc 2006, 7:90-95.
16. Gruber-Baldini A.L., Stuart B., Zuckerman I.H., et al. Treatment of dementia in community-dwelling and institutionalized Medicare beneficiaries. J Am Geriatr Soc 2007, 55:1508-1516.
17. Seitz D.P., Gruneir A., Conn D.K., Rochon P.A. Cholinesterase inhibitor use in U.S. nursing homes: Results from the National Nursing Home Survey. J Am Geriatr Soc 2009, 57:2269-2274.
18. Hosia-Randell H., Pitkälä K. Use of psychotropic drugs in elderly nursing home residents with and without dementia in Helsinki, Finland. Drugs Aging 2005, 22:793-800.
19. Barro-Belaygues N., van Kan G.A., Rolland Y., et al. Patterns of dementia treatment use in assisted living facilities: A cross-sectional study of 1975 demented residents. J Am Med Dir Assoc 2011, 12:648-654.
20. Lattanzio F., Mussi C., Scafato E., et al. Health care for older people in Italy: The U.L.I.S.S.E. Project (Un Link Informatico sui Servizi Sanitari Esistenti per l'anziano; a computerized network on health care services for older people). J Nutr Health Aging 2010, 14:238-242.
21. Ruggiero C., Lattanzio F., Dell'Aquila G., et al. Inappropriate drug prescriptions among older nursing-home residents: The Italian perspective. Drugs Aging 2009, 26:15-30.
22. Morris J.N., Fries B.E., Dr Mehr, et al. MDS Cognitive Performance Scale. J Gerontol 1994, 49:M174-M182.
23. Hartmaier S.L., Sloane P.D., Guess H.A., et al. Validation of the Minimum Data Set Cognitive Performance Scale: Agreement with the Mini-Mental State Examination. J Gerontol 1995, 50:M128-M133.
24. Paquay L., De Lepeleire J., Schoenmakers B., et al. Comparison of the diagnostic accuracy of the Cognitive Performance Scale (Minimum Data Set) and the Mini-Mental State Examination for the detection of cognitive impairment in nursing home residents. Int J Geriatr Psychiatry 2007, 22:286-293.
25. van der Steen J.T., Mehr D.R., Kruse R.L., et al. Dementia, lower respiratory tract infection, and long-term mortality. J Am Med Dir Assoc 2007, 8:396-403.
26. van der Steen J.T., Volicer L., Gerritsen D.L., et al. Defining severe dementia with the Minimum Data Set. Int J Geriatr Psychiatry 2006, 21:1099-1106.
27. Alzola C, Harrel F. An Introduction to S and The Hmisc and Design Libraries, URL, 2006. Available at: Accessed February 15, 2012. http://cran.r-project.org/.
28. Bates D, Sarkar D. lme4: Linear mixed-effects models using S4 classes. R package version 0.9975-12, URL, 2007. Available at: Accessed February 15, 2012. http://cran.r-project.%20org/.
29. O'Brien J.A., Caro J.J. Alzheimer's disease and other dementia in nursing homes: Levels of management and cost. Int Psychogeriatr 2001, 13:347-358.
30. van Doorn C., Gruber-Baldini A.L., Zimmerman S., et al. Dementia as a risk factor for falls and fall injuries among nursing home residents. J Am Geriatr Soc 2003, 51:1213-1218.
31. Schneider L.S., Dagerman K.S., Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: Metaanalysis of randomized placebo-controlled trials. JAMA 2005, 294:1934-1943.
32. Schneider L.S., Tariot P.N., Dagerman K.S., et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 2006, 355:1525-1538.
33. Franco K.N., Messinger-Rapport B. Pharmacological treatment of neuropsychiatric symptoms of dementia: A review of the evidence. J Am Med Dir Assoc 2006, 7:201-202.
34. Cornegé-Blokland E., Kleijer B.C., Hertogh C.M., van Marum R.J. Reasons to prescribe antipsychotics for the behavioral symptoms of dementia: A survey in Dutch nursing homes among physicians, nurses, and family caregivers. J Am Med Dir Assoc 2012, 13:80.e1-80.e6.
35. Galik E.M., Resnick B., Gruber-Baldini A., et al. Pilot testing of the Restorative Care Intervention for the Cognitively Impaired. J Am Med Dir Assoc 2008, 9:516-522.
36. Christensen M.D., White H.K. Dementia assessment and management. J Am Med Dir Assoc 2006, 7:109-118.
37. Buhr G.T., White H.K. Difficult behaviors in long-term care patients with dementia. J Am Med Dir Assoc 2006, 7:180-192.
38. Smith D.A. Behavioral problems and symptoms in dementia. J Am Med Dir Assoc 2008, 9:622-625.
39. Sørensen L., Foldspang A., Gulmann N.C., et al. Assessment of dementia in nursing home residents by nurses and assistants: Criteria validity and determinants. Int J Geriatr Psychiatry 2001, 16:615-621.
40. MacDonald A.J.D., Carpenter G.I. The recognition of dementia in 'non-EMI' nursing home residents in South East England. Int J Geriatr Psychiatry 2003, 18:105-108.
41. Consensus statement on improving the quality of mental health care in US nursing homes: Management of depression and behavioral symptoms associated with dementia. J Am Geriatr Soc 2003, 51:1287-1298. American Geriatrics Society; American Association for Geriatric Psychiatry.
42. Tsolaki M., Papaliagkas V., Anogianakis G., et al. European Alzheimer Disease Consortium. Consensus statement on dementia education and training in Europe. J Nutr Health Aging 2010, 14:131-135.
43. Reynish E., Cortes F., Andrieu S., et al. ICTUS Study Group. The ICTUS Study: A prospective longitudinal observational study of 1,380 AD patients in Europe. Study design and baseline characteristics of the cohort. Neuroepidemiology 2007, 29:29-38.
44. Parsons C., Briesacher B.A., Givens J.L., et al. Cholinesterase inhibitor and memantine use in newly admitted nursing home residents with dementia. J Am Geriatr Soc 2011, 59:1253-1259.
45. O'Brien J.T., Burns A. Clinical practice with anti-dementia drugs: A revised (second) consensus statement from the British Association for Psychopharmacology. J Psychopharmacol 2011, 25:997-1019. BAP Dementia Consensus Group.
46. Winblad B., Kilander L., Eriksson S., et al. Donepezil in patients with severe Alzheimer's disease: Double-blind, parallel-group, placebo-controlled study. Lancet 2006, 367:1057-1065.
47. Blesa R., Davidson M., Kurz A., et al. Galantamine provides sustained benefits in patients with 'advanced moderate' Alzheimer's disease for at least 12 months. Dement Geriatr Cogn Disord 2003, 15:79-87.
48. Tariot P.N. Medical management of advanced dementia. J Am Geriatr Soc 2003, 51:S305-S313.
49. Winblad B., Black S.E., Homma A., et al. Donepezil treatment in severe Alzheimer's disease: A pooled analysis of three clinical trials. Curr Med Res Opin 2009, 25:2577-2587.
50. Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer's disease (Review). The Cochrane Library 2009, Issue 1. Available at: Accessed February 15, 2012. http://www.thecochranelibrary.com.
51. Kerwin D., Claus T.H. Severe Alzheimer's disease: Treatment effects on function and care requirements. J Am Med Dir Assoc 2011, 12:99-104.
52. Qaseem A., Snow V., Cross J.T., et al. Current pharmacologic treatment of dementia: A clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med 2008, 148:370-378.
53. Winblad B., Poritis N. Memantine in severe dementia: Results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 1999, 14:135-146.
54. Wilcock G., Mbius H.J., Stffler A. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol 2002, 17:297-305. MMM 500 Group.
55. Orgogozo J.M., Rigaud A.S., Stffler A., et al. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: A randomized, placebo-controlled trial (MMM 300). Stroke 2002, 33:1834-1839.
56. Reisberg B., Doody R., Stffler A., et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003, 348:1333-1341.
57. Tariot P.N., Farlow M.R., Grossberg G.T., et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: A randomized controlled trial. JAMA 2004, 291:317-324.
58. Peskind E.R., Potkin S.G., Pomara N., et al. Memantine treatment in mild to moderate Alzheimer disease: A 24-week randomized, controlled trial. Am J Geriatr Psychiatry 2006, 14:704-715.